BioMS Medical Announces Positive Interim Analysis On Phase III Trial Of Dirucotide (MBP8298) For Multiple Sclerosis

BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and European study of dirucotide (MBP8298) in patients with secondary progressive MS.

More: continued here

Filed under: Multiple Sclerosis on September 8th, 2008